Mr. Chair, the problem of resistance is really an important problem. As in the past, Southeast Asia is often historically the region where the first problem of resistance occurs, meaning that the actual medicine called ACT, which was working very well, doesn't work as well anymore. We see some limited cases of resistance, and the WHO and other partners are working to make sure that we geographically contain that problem of resistance before we try to eliminate that problem.
The risk could be that the problem of resistance could spread to other regions—and, to be honest, that would be catastrophic. That's why many countries, the Global Vaccine and Immunization Research Forum, Bill Gates, and others invest a lot of money in that region at the moment. It's also why the research and development community is trying to work on a potential new generation of medicines for the future, and maybe MMV could develop that a bit more.